Fig. 11.1 The major T cell-based immunotherapeutic targets and their tumor or antigen-presenting cell ligands. The activation of T cells and their conversion to a cytotoxic phenotype is governed by…
Gene mutation Serous tumor of LMP Low-grade serous carcinoma References TP53 0–8 % 0–8.3 % [30, 82] KRAS 33–61.8 % 19–41 % [11, 31, 82, 108] BRAF 14.5–28 % 2–33…
Fig. 10.1 Criteria for decision making When Should the Relapse Be Treated? In most of cases, CA 125 elevation is the first signal of recurrence; it can be observed some…
Items Possible responses (score) A Has food intake declined over the past 3 months due to loss of appetite, digestive problems, chewing or swallowing difficulties? 0 = severe decrease…
© Springer International Publishing Switzerland 2017Eric Pujade-Lauraine, Isabelle Ray-Coquard and Fabrice Lécuru (eds.)Ovarian Cancers10.1007/978-3-319-32110-3_8 8. First-Line Systemic Therapy (Chemo/Antiangiogenics) Sandro Pignata1 and Sabrina Chiara Cecere1 (1) Division of Medical Oncology, Department of Uro-Gynaecological Oncology, Istituto Nazionale Tumori Fondazione G…
NCT# Name Type – site Objective MRI NCT02243059 MILO Maastricht University Medical Center Magnetic resonance imaging for lymph node staging in ovarian cancer NCT02334371 Maastricht University Medical Center MR-PET for…
Author Year of publication Patients n Relapses n (%) FIGO stage IA FIGO stage IC Histological type Grade 1 Grade 2 Grade 3 Grade 1 Grade 2 Grade 3 Serous…
FIGO stage Intra-abdominal residual disease Radiological and clinically negative LN Positive lymph nodes >1 cm FIGO I–II 0 >0: stop doing surgery for ovarian cancer Yes Complete surgical staging −/−…
Author (year) N (Period recruitment /year) Timing Drug (mg/m2) Mortality PFS median months OS median months Cotte (2007) [39] 81 (14) M Cis (20) 2.5 % 19 28 Pavlov (2009)…
Study n % optimal primary surgery % optimal interval surgery PFS primary PFS interval OS primary OS interval EORTC [15] 319 0 45 % 13 months 18 months 20 months…
